

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

203568Orig1s000

LABELING

-----**HIGHLIGHTS OF PRESCRIBING INFORMATION**-----

These highlights do not include all the information needed to use KYNAMRO safely and effectively. See full prescribing information for KYNAMRO.

KYNAMRO (mipomersen sodium) Injection
Solution for Subcutaneous Injection
Initial U.S. Approval: 2013

WARNING: RISK OF HEPATOTOXICITY

See full prescribing information for complete boxed warning.

KYNAMRO can cause elevations in transaminases (5.1).

- Measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended (2.3, 5.1)
- During treatment, withhold the dose of KYNAMRO if the ALT or AST is ≥ 3 times the upper limit of normal (ULN) (2.3, 5.1).
- Discontinue KYNAMRO for clinically significant liver toxicity (2.3, 5.1).

KYNAMRO increases hepatic fat (hepatic steatosis) with or without concomitant increases in transaminases (5.1).

- Hepatic steatosis associated with KYNAMRO may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis (5.1). Because of the risk of hepatotoxicity, KYNAMRO is available only through a restricted program called the KYNAMRO REMS (5.2).

-----**INDICATIONS AND USAGE**-----

KYNAMRO™ is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH) (1).

Limitations of Use:

- The safety and effectiveness of KYNAMRO have not been established in patients with hypercholesterolemia who do not have HoFH.
- The effect of KYNAMRO on cardiovascular morbidity and mortality has not been determined.
- The use of KYNAMRO as an adjunct to LDL apheresis is not recommended.

-----**DOSAGE AND ADMINISTRATION**-----

- 200 mg once weekly as a subcutaneous injection (2.1)
- Before treatment, measure ALT, AST, alkaline phosphatase, and total bilirubin (2.1)

-----**DOSAGE FORMS AND STRENGTHS**-----

- Single-use vial containing 1 mL of a 200 mg/mL solution (3)
- Single-use pre-filled syringe containing 1 mL of a 200 mg/mL solution (3)

-----**CONTRAINDICATIONS**-----

- Moderate or severe hepatic impairment, or active liver disease, including unexplained persistent elevations of serum transaminases (4)
- Known sensitivity to product components (4)

-----**WARNINGS AND PRECAUTIONS**-----

- Injection site reactions occur in 84% of patients and typically consist of one or more of the following: erythema, pain, tenderness, pruritus and local swelling (5.3)
- Flu-like symptoms, which typically occur within 2 days after an injection, occur in 30% of patients and include one or more of the following: influenza-like illness, pyrexia, chills, myalgia, arthralgia, malaise or fatigue (5.4)

-----**ADVERSE REACTIONS**-----

The most commonly reported adverse reactions (incidence $\geq 10\%$ and greater than placebo) are injection site reactions, flu-like symptoms, nausea, headache and elevations in serum transaminases, specifically ALT. (5.4, 6).

-----**USE IN SPECIFIC POPULATIONS**-----

- Nursing mothers: Discontinue drug or nursing (8.3).
- Pediatric Patients: Safety and effectiveness not established (8.4).

To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling

Revised 1/2013

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: RISK OF HEPATOTOXICITY

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 General Dosing Information
- 2.2 Administration
- 2.3 Adjustments for Patients Developing Transaminase Elevations

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Risk of Hepatotoxicity
- 5.2 KYNAMRO REMS
- 5.3 Injection Site Reactions
- 5.4 Flu-Like symptoms

6 ADVERSE REACTIONS

- 6.1 Clinical Trials

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers

- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Females of Reproductive Potential
- 8.7 Renal Impairment
- 8.8 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Pharmacology and/or Toxicology

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION**WARNING: RISK OF HEPATOTOXICITY**

KYNAMRO can cause elevations in transaminases. In the KYNAMRO clinical trial in patients with HoFH, 4 (12%) of the 34 patients treated with KYNAMRO compared with 0% of the 17 patients treated with placebo had at least one elevation in alanine aminotransferase (ALT) ≥ 3 x upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR) or partial thromboplastin time (PTT) [see *Warnings and Precautions (5.1)*].

KYNAMRO also increases hepatic fat, with or without concomitant increases in transaminases. In the trials in patients with heterozygous familial hypercholesterolemia (HeFH) and hyperlipidemia, the median absolute increase in hepatic fat was 10% after 26 weeks of treatment, from 0% at baseline, measured by magnetic resonance imaging (MRI). Hepatic steatosis is a risk factor for advanced liver disease; including steatohepatitis and cirrhosis [see *Warnings and Precautions (5.1)*].

Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT, AST regularly as recommended. During treatment, withhold the dose of KYNAMRO if the ALT or AST are ≥ 3 x ULN. Discontinue KYNAMRO for clinically significant liver toxicity [see *Dosage and Administration (2.3)* and *Warnings and Precautions (5.1)*].

Because of the risk of hepatotoxicity, KYNAMRO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYNAMRO REMS [see *Warnings and Precautions (5.2)*].

1 INDICATIONS AND USAGE

KYNAMRO™ is indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of Use

- The safety and effectiveness of KYNAMRO have not been established in patients with hypercholesterolemia who do not have HoFH.
- The effect of KYNAMRO on cardiovascular morbidity and mortality has not been determined.

- 39 • The safety and effectiveness of KYNAMRO as an adjunct to LDL apheresis have
40 not been established; therefore, the use of KYNAMRO as an adjunct to LDL
41 apheresis is not recommended.
42

43 **2 DOSAGE AND ADMINISTRATION**

44 **2.1 General Dosing Information**

45 Before beginning treatment with KYNAMRO, measure transaminases (ALT, AST),
46 alkaline phosphatase, and total bilirubin [see *Warnings and Precautions (5.1)*].

47 The recommended dose of KYNAMRO is 200 milligrams (mg) once weekly as a
48 subcutaneous injection.

49 KYNAMRO is intended for subcutaneous use only. Do not administer intramuscularly
50 or intravenously.

51 The injection should be given on the same day every week, but if a dose is missed, the
52 injection should be given at least 3 days from the next weekly dose

53 After initiation of KYNAMRO therapy lipid levels should be monitored at least every 3
54 months for the first year. Maximal reduction of LDL-C may be seen with KYNAMRO
55 therapy after approximately 6 months (based on the time to steady state seen in clinical
56 studies). Health care providers should assess the patient's LDL-C level after 6 months to
57 determine if the LDL-C reduction achieved with KYNAMRO is sufficiently robust to
58 warrant the potential risk of liver toxicity.

59

60 **2.2 Administration**

61 Each vial or pre-filled syringe of KYNAMRO provides 200 mg of mipomersen sodium in
62 a deliverable volume of 1 milliliter (mL) of solution and is intended for single-use only.

63 The KYNAMRO vial or pre-filled syringe should be removed from 2-8°C (36-46°F)
64 refrigerated storage and allowed to reach room temperature for at least 30 minutes prior
65 to administration.

66 Parenteral drug products should be inspected visually prior to administration. If the
67 solution is cloudy or contains visible particulate matter, the contents must not be injected
68 and the product should be returned to the pharmacy.

69 The first injection administered by the patient or caregiver should be performed under the
70 guidance and supervision of an appropriately qualified health care professional.

71 KYNAMRO should be injected into the abdomen, thigh region, or outer area of the upper
72 arm. KYNAMRO should not be injected in areas of active skin disease or injury such as
73 sunburns, skin rashes, inflammation, skin infections, active areas of psoriasis, etc. Areas
74 of tattooed skin and scarring should also be avoided.

75

76 **2.3 Adjustments for Patients Developing Transaminase Elevations**

77

78 Table 1 summarizes recommendations for monitoring for patients who develop elevated
79 transaminases during therapy with KYNAMRO [see *Warnings and Precautions (5.1)*].
80

81 **Table 1: Monitoring for Patients With Elevated Transaminases**

| ALT OR AST | TREATMENT AND MONITORING RECOMMENDATIONS* |
|------------------|--|
| ≥3x and < 5x ULN | <ul style="list-style-type: none"> • Confirm elevation with a repeat measurement within one week. • If confirmed, withhold dosing, obtain additional liver-related tests if not already measured (such as total bilirubin, alkaline phosphatase and INR) and investigate to identify the probable cause. • If resuming KYNAMRO after transaminases resolve to <3x ULN consider monitoring liver-related tests more frequently. |
| ≥5x ULN | <ul style="list-style-type: none"> • Withhold dosing, obtain additional liver-related tests if not already measured (such as total bilirubin, alkaline phosphatase and INR) and investigate to identify the probable cause. • If resuming KYNAMRO after transaminases resolve to < 3x ULN, monitor liver-related tests more frequently. |

82 * Recommendations based on an ULN of approximately 30-40 international units/L.

83

84 If transaminase elevations are accompanied by clinical symptoms of liver injury (e.g.,
85 nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms),
86 increases in bilirubin ≥2x ULN, or active liver disease, discontinue treatment with
87 KYNAMRO and investigate to identify the probable cause [see *Warnings and*
88 *Precautions (5.1)*].

89

90 **3 DOSAGE FORMS AND STRENGTHS**

- 91 • Single-use vial containing 1 mL of a 200 mg/mL clear, colorless to slightly yellow
92 solution.
- 93 • Single-use pre-filled syringe containing 1 mL of a 200 mg/mL clear, colorless to
94 slightly yellow solution.

95

96 **4 CONTRAINDICATIONS**

97 KYNAMRO is contraindicated in the following conditions:

- 98 • Moderate or severe hepatic impairment (Child-Pugh B or C) or active liver
99 disease, including unexplained persistent elevations of serum transaminases [see
100 *Warnings and Precautions (5.1) and Use in Specific Populations (8.8)*]
- 101 • Patients with a known hypersensitivity to any component of this product [see
102 *Adverse Reactions (6.1)*].

103

104 **5 WARNINGS AND PRECAUTIONS**

105 **5.1 Risk of Hepatotoxicity**

106 KYNAMRO can cause elevations in transaminases and hepatic steatosis, as described
107 below. To what extent KYNAMRO-associated hepatic steatosis promotes the elevations
108 in transaminases is unknown. There is concern that KYNAMRO could induce
109 steatohepatitis, which can progress to cirrhosis over several years. The clinical studies
110 supporting the safety and efficacy of KYNAMRO in HoFH would have been unlikely to
111 detect this adverse outcome given their size and duration [see *Clinical Studies (14)*].

112

113 Elevation of Transaminases

114 KYNAMRO can cause increases in serum transaminases (alanine aminotransferase
115 [ALT] and/or aspartate aminotransferase [AST]). In the clinical trial, 4 (12%) of the 34
116 subjects with HoFH treated with KYNAMRO compared to 0% of the 17 subjects treated
117 with placebo had an elevation in ALT $\geq 3x$ ULN, and 3 (9%) of those treated with
118 KYNAMRO compared to 0% treated with placebo had at least one elevation in ALT $\geq 5x$
119 ULN.

120 Measure a full liver panel to include ALT, AST, total bilirubin, and alkaline phosphatase
121 before initiation of treatment with KYNAMRO [see *Dosage and Administration (2.1)*].
122 KYNAMRO is contraindicated in patients with moderate or severe hepatic impairment,
123 or active liver disease, including unexplained persistent elevations of serum
124 transaminases. If the baseline liver-related tests are abnormal, consider initiating
125 KYNAMRO after an appropriate work-up and the baseline abnormalities are explained or
126 resolved. During the first year, conduct liver-related tests monthly (ALT and AST, at a
127 minimum). After the first year, conduct these tests at least every 3 months. Discontinue
128 KYNAMRO for persistent or clinically significant elevations [see *Dosage and*
129 *Administration (2.3)*].

130 If transaminase elevations are accompanied by clinical symptoms of liver injury (e.g.,
131 nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms),
132 increases in bilirubin $\geq 2x$ ULN, or active liver disease, discontinue treatment with
133 KYNAMRO and identify the probable cause.

134

135 Hepatic Steatosis

136 KYNAMRO increases hepatic fat (steatosis) with or without concomitant increases in
137 transaminases [see *Adverse Reactions (6.1)*]. Hepatic steatosis is a risk factor for
138 advanced liver disease, including steatohepatitis and cirrhosis. The long-term
139 consequences of hepatic steatosis associated with KYNAMRO therapy are unknown.
140 During the clinical trials in patients with heterozygous familial hypercholesterolemia
141 (HeFH) and hyperlipidemia, the median absolute increase in hepatic fat was 10% after 26
142 weeks of treatment, from 0% at baseline, measured by magnetic resonance imaging
143 (MRI).

144 Alcohol may increase levels of hepatic fat and induce or exacerbate liver injury. It is
145 recommended that patients taking KYNAMRO should consume no more than one
146 alcoholic drink per day.

147 Caution should be exercised when KYNAMRO is used with other medications known to
148 have potential for hepatotoxicity, for example isotretinoin, amiodarone, acetaminophen
149 (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. The effect of
150 concomitant administration of KYNAMRO with other hepatotoxic medications is
151 unknown. More frequent monitoring of liver-related tests may be warranted.

152 Mipomersen has not been studied concomitantly with other LDL-lowering agents that
153 can also increase hepatic fat. Therefore, the combined use of such agents is not
154 recommended.

155

156 **5.2 KYNAMRO REMS**

157 Because of the risk of hepatotoxicity, KYNAMRO is available only through a limited
158 program under the REMS. Under the KYNAMRO REMS, only certified healthcare
159 providers and pharmacies may prescribe and distribute KYNAMRO. Further information
160 is available at www.KynamroREMS.com or by telephone at 1-877-KYNAMRO (1-877-
161 596-2676).

162

163 **5.3 Injection Site Reactions**

164 Injection site reactions have been reported in 84% of patients receiving KYNAMRO
165 therapy. These local reactions typically consist of one or more of the following:
166 erythema, pain, tenderness, pruritus and local swelling. Injection site reactions do not
167 occur with all injections but resulted in discontinuation of therapy in 5% of patients in
168 pooled Phase 3 trials. [See *Adverse Reactions (6.1)*] To minimize the potential for
169 injection site reactions, proper technique for subcutaneous administration should be
170 followed. [see *Patient Counseling Information (17)*]

171

172 **5.4 Flu-Like Symptoms**

173 Flu-like symptoms have been reported in 30% of patients receiving KYNAMRO therapy
174 and include one or more of the following: influenza-like illness, pyrexia, chills, myalgia,
175 arthralgia, malaise or fatigue. Flu-like symptoms, which typically occur within 2 days
176 after an injection, do not occur with all injections but resulted in discontinuation of
177 therapy in 3% of patients in pooled Phase 3 trials. [See *Adverse Reactions (6.1)*]

178

179 **6 ADVERSE REACTIONS**

180 The following important adverse reactions have been observed and are discussed in detail
181 in other sections of the label:

- 182 • Risk of hepatotoxicity [see *Warnings and Precautions (5.1)*]

183

184 **6.1 Clinical Trials**

185 Because clinical trials are conducted under widely varying conditions, adverse reaction
186 rates observed in clinical trials of a drug cannot be directly compared to rates in the
187 clinical trial of another drug and may not reflect the rates observed in patients in clinical
188 practice.

189 Safety data are based on pooled results from four Phase 3, randomized, double-blind,
190 placebo-controlled trials with a total of 390 patients of which 261 patients received
191 weekly subcutaneous injections of 200 mg of KYNAMRO and 129 patients received
192 placebo for a median treatment duration of 25 weeks (age range 12-81 years, 47%
193 women, 84% Caucasian, 10% Blacks, 3% Asian, 3% other). For the 141 participants
194 who subsequently enrolled in the open-label extension trial, the mean length of study
195 treatment, including exposure to KYNAMRO in the index study, was 19.8 months and
196 the median was 18.2 months. A total of 41 individuals with HoFH were exposed to
197 KYNAMRO for at least 6 months and 25 were exposed for at least 12 months.

198 Eighteen percent of patients on KYNAMRO and 2% of patients on placebo discontinued
199 treatment due to adverse reactions. The five most common adverse reactions in patients
200 treated with KYNAMRO that led to treatment discontinuation and occurred at a rate
201 greater than placebo were: injection site reactions (5.0%), alanine aminotransferase
202 increased (3.4%), flu-like symptoms (2.7%), aspartate aminotransferase increased (2.3%),
203 and liver function test abnormal (1.5%).

204 Common Adverse Reactions

205 Table 2 enumerates adverse reactions that occurred among pooled Phase 3 patients
206 treated with KYNAMRO at an incidence that was at least 2% more than that observed in
207 the placebo-treated patients, listed by system organ class and frequency (MedDRA
208 v.13.0). Similar types and severities of adverse reactions were observed across all
209 populations in this pooled table including the subset of patients with HoFH.

210 **Table 2: Summary of Adverse Reactions for Pooled Phase 3 Placebo-Controlled**
211 **Trials**

| System Organ Class Preferred Term | Treatment Group | |
|---|---------------------------|---------------------------|
| | KYNAMRO (%) (N=261) | Placebo (%) (N=129) |
| Total Patients with Events | 95% | 85% |
| Cardiac disorders | 9% | 6% |
| Angina pectoris | 4% | 2% |
| Palpitations | 3% | 0% |
| Gastrointestinal disorders | 30% | 29% |
| Nausea | 14% | 8% |
| Vomiting | 4% | 2% |
| Abdominal pain | 3% | 1% |
| General disorders and administration site conditions | 87% | 47% |
| Injection site reactions* | 84% | 33% |
| Fatigue | 15% | 8% |

PROPOSED TEXT OF THE LABELING OF THE DRUG

| System Organ Class Preferred Term | Treatment Group | |
|--|---------------------------|---------------------------|
| | KYNAMRO (%) (N=261) | Placebo (%) (N=129) |
| Influenza like illness | 13% | 3% |
| Pyrexia | 8% | 3% |
| Chills | 6% | 1% |
| Edema peripheral | 5% | 2% |
| Hepatobiliary disorders | 9% | 5% |
| Hepatic steatosis | 7% | 2% |
| Investigations | 30% | 15% |
| Alanine aminotransferase increased | 10% | 1% |
| Aspartate aminotransferase increased | 6% | 2% |
| Liver function test abnormal | 5% | 1% |
| Hepatic enzyme increased | 3% | 1% |
| Musculoskeletal and connective tissue disorders | 26% | 26% |
| Pain in extremity | 7% | 3% |
| Musculoskeletal pain | 4% | 2% |
| Nervous system disorders | 25% | 17% |
| Headache | 12% | 9% |
| Psychiatric disorders | 10% | 3% |
| Insomnia | 3% | 1% |
| Vascular disorders | 11% | 5% |
| Hypertension | 7% | 3% |

* Preferred Terms include: Injection site erythema, Injection site pain, Injection site hematoma, Injection site pruritus, Injection site swelling, Injection site discoloration, Injection site nodule, Injection site rash, Injection site warmth, Injection site induration, Injection site recall reaction, Injection site edema, Injection site hemorrhage, Injection site discomfort, Injection site reaction, Injection site papule, Injection site inflammation, Injection site macule, Injection site vesicles, Injection site urticaria

212 In the pooled Phase 3 trials, neoplasms (benign and malignant) were reported in 4% of
 213 patients receiving KYNAMRO and 0% of patients receiving placebo. In addition, 9% of
 214 patients receiving KYNAMRO and 3% of patients receiving placebo developed 1+ or
 215 greater proteinuria by dipstick measurement by the end of the trial.

216 In the open-label extension trial, one case of hypersensitivity reaction with angioedema
 217 and one case of glomerular nephritis were reported.

218 Transaminase Elevations

219 In the pooled, placebo-controlled clinical trials with KYNAMRO, elevated serum
 220 transaminase levels, mainly ALT, have been observed as presented in Table 3. Elevated
 221 ALT levels $\geq 3X$ ULN have been reported on two consecutive occasions at least 7 days
 222 apart in 8.4% of patients receiving KYNAMRO therapy (versus 0% of placebo patients)
 223 with 16.5% of patients receiving KYNAMRO therapy having at least 1 result that was
 224 $\geq 3X$ ULN (versus 0.8% for placebo patients). The ALT elevations observed in the
 225 pooled, placebo-controlled trials were generally accompanied by lesser AST elevations
 226 and were not associated with increased total bilirubin, changes in INR or PTT, nor by

227 decreased albumin levels. After stopping therapy, in the patients in whom an elevation
 228 was observed, transaminase elevations trended toward baseline over a period of weeks to
 229 months.

230 **Table 3: Transaminase Results for Pooled Phase 3 Placebo-Controlled Trials**

| Parameter | Statistic | Kynamro (%) (N=261) | Placebo (%) (N=129) |
|-------------|---|------------------------|------------------------|
| ALT maximum | Incidence rate, % | | |
| | ≥ 3 x ULN and < 5 x ULN | 12% | 1% |
| | ≥ 5 x ULN and < 10 x ULN | 3% | 0% |
| | ≥ 10 x ULN | 1% | 0% |
| ALT | ≥ 3 x ULN, two consecutive results (at least 7 days apart), % | 8% | 0% |
| AST maximum | Incidence rate, % | | |
| | ≥ 3 x ULN and < 5 x ULN | 7% | 1% |
| | ≥ 5 x ULN and < 10 x ULN | 3% | 0% |
| | ≥ 10 x ULN | 0% | 0% |
| AST | ≥ 3 x ULN, two consecutive results (at least 7 days apart), % | 4% | 0% |

Adults: ALT ULN= 41 U/L; AST ULN = 34 U/L

231 Hepatic Steatosis

232 Increases in liver fat as measured by MRI were greater in patients receiving KYNAMRO
 233 therapy than in patients receiving placebo. Data from Phase 3 supportive trials in patients
 234 with heterozygous familial hypercholesterolemia and coronary artery disease and in
 235 patients with high risk hypercholesterolemia demonstrated after 26 weeks of treatment, a
 236 median nominal increase in fat fraction of 9.6% relative to baseline following
 237 KYNAMRO therapy versus a nominal 0.02% change in the placebo group (mean
 238 increases were 12.2% mipomersen vs 0.4% placebo). The maximum change in fat
 239 fraction was 46% for the KYNAMRO group and 28% for the placebo group. Sixty-two
 240 percent of patients receiving KYNAMRO developed a 5% or greater increase in hepatic
 241 fat versus 8% of patients receiving placebo. In general, these elevations in fat fraction
 242 decreased when assessed by MRI performed 24 weeks after cessation of KYNAMRO in
 243 the Phase 3 trial of patients with high-risk hypercholesterolemia. In the open-label
 244 extension trial, among individuals with a measurement at baseline and at 12 months or
 245 longer on KYNAMRO, 25% had an average liver fat fraction > 20% on at least one
 246 occasion.

247 Injection Site Reactions

248 The most commonly-reported adverse reactions were injection site reactions occurring in
 249 84% of patients receiving KYNAMRO versus 33% of placebo treated patients. The most
 250 common injection site reactions were erythema (59%), pain (56%), hematoma (32%),

251 pruritus (29%), swelling (18%) and discoloration (17%). Injection site reactions did not
252 occur with every injection. Injection site reactions resulted in discontinuation of
253 KYNAMRO in 5% of patients. Recall reactions, consisting of local erythema, tenderness
254 and/or pruritus at previous injection sites when subsequent injections were administered,
255 were observed in 8% of patients, all of whom were receiving KYNAMRO.

256 Flu-like Symptoms

257 Flu-like symptoms, defined as any one of the following: influenza-like illness, pyrexia,
258 chills, myalgia, arthralgia, malaise or fatigue and occurring within 2 days of injection,
259 have been reported more frequently in patients receiving KYNAMRO (29.9%) versus
260 placebo (16.3%) in the pooled Phase 3 studies. Flu-like symptoms did not occur with all
261 injections. Flu-like symptoms resulted in discontinuation of KYNAMRO in 2.7% of
262 patients. In the open-label extension trial, in which all patients received KYNAMRO
263 therapy, 66% reported flu-like symptoms, 25% discontinued treatment due to flu-like
264 symptoms and 9% experienced severe flu-like symptoms.

265 Immunogenicity

266 In the pooled Phase 3 trials, 38% of KYNAMRO-treated patients tested positive for anti-
267 KYNAMRO antibodies during the 6-month trials. Efficacy results in the Phase 3 trials in
268 patients who tested positive for anti-KYNAMRO antibodies were similar to patients who
269 remained negative for antibodies (mean LDL-C percent change from baseline was -32%
270 for antibody-positive and -34% for antibody-negative participants). In the open-label
271 extension trial, approximately 72% of patients receiving KYNAMRO therapy tested
272 positive for anti-KYNAMRO antibodies (35% with titers >3200). The incidence of flu-
273 like symptoms and the incidence of discontinuation of KYNAMRO were higher in
274 antibody-positive patients. Antibodies to KYNAMRO were associated with higher
275 trough levels for the drug. The detection of antibody formation is highly dependent on the
276 sensitivity and specificity of the assay. Additionally, the observed incidence of antibody
277 (including neutralizing antibody) positivity in an assay may be influenced by several
278 factors including assay methodology, sample handling, timing of sample collection,
279 concomitant medications, and underlying disease. For these reasons, comparison of the
280 incidence of antibodies to KYNAMRO with the incidence of antibodies to other products
281 may be misleading.

282

283 **7 DRUG INTERACTIONS**

284 No clinically relevant pharmacokinetic interactions were reported between KYNAMRO
285 and warfarin, or between KYNAMRO and simvastatin or ezetimibe [see *Clinical*
286 *Pharmacology* (12.3)]. Additionally, coadministration of KYNAMRO with warfarin did
287 not result in a pharmacodynamic interaction as determined by INR, aPTT and PT.

288

289 **8 USE IN SPECIFIC POPULATIONS**

290 **8.1 Pregnancy**

291 Pregnancy Category B

292 There are no adequate and well-controlled studies in pregnant women. Reproduction and
293 embryofetal development studies performed in mice at doses up to 87.5 mg/kg/wk given
294 by subcutaneous administration from mating through organogenesis and in pregnant
295 rabbits given 52.5 mg/kg/wk, show no evidence of impaired fertility or harm to the fetus
296 at 2 (mice) to 5 (rabbits) times clinical exposure at a 200 mg/wk therapeutic dose.
297 Because animal reproduction studies are not always predictive of the human response,
298 this drug should be used during pregnancy only if clearly needed.

299 Pregnant rats given subcutaneous doses of 7, 35, 70 mg/kg/wk mipomersen sodium from
300 gestation day 6 through weaning on lactation day 20, resulted in decreased rat pup
301 survival at 70 mg/kg/wk, 3-times clinical exposure at a 200 mg/wk therapeutic dose
302 based on body surface area comparisons across species. Dose related decreases in pup
303 body weights, impaired reflexes and grip strength were observed at 35 mg/kg/wk (2-
304 times the anticipated human dose. Levels of mipomersen in rat milk were very low
305 (≤ 0.92 $\mu\text{g/mL}$ at subcutaneous doses up to 70 mg/kg/wk). Due to the poor oral
306 bioavailability of mipomersen sodium, it was considered unlikely that these low milk
307 exposure levels adversely affected the pups during lactation.

308

309 **8.3 Nursing Mothers**

310 It is not known whether KYNAMRO is excreted in human milk. Because many drugs
311 are excreted in human milk a decision should be made whether to discontinue nursing or
312 discontinue the drug, taking into account the importance of the drug to the mother.

313 Levels of mipomersen present in rat milk were low (≤ 0.92 $\mu\text{g/mL}$) given subcutaneous
314 doses up to 70 mg/kg/wk. Oral bioavailability is expected to be less than 10%. However
315 a risk to newborns/infants cannot be excluded, therefore caution should be used when
316 KYNAMRO is administered to a nursing woman.

317 Lactating rats administered mipomersen sodium at doses up to 70 mg/kg/wk (3-times the
318 anticipated systemic exposure from a 200 mg/wk dose, based on body surface area
319 comparison) consumed less food while nursing. This correlated with reduced weight
320 gain in the rat pups, and decreased pup survival in litters of dams given 70 mg/kg/wk.

321

322 **8.4 Pediatric Use**

323 Safety and effectiveness have not been established in pediatric patients.

324

325 A juvenile toxicity study was conducted in rats at doses up to 50 mg/kg/wk (2-times the
326 systemic exposure from a 200 mg/wk clinical dose based on body surface area
327 comparisons). Doses ≥ 10 mg/kg/wk were associated with reduced body weight gain in
328 young rats, but had no effect on long bone growth or sexual development.

329

330 **8.5 Geriatric Use**

331 Clinical studies of KYNAMRO did not include sufficient numbers of patients aged 65
332 and over to determine whether they respond differently from younger patients. Of the 51
333 patients enrolled in the Phase 3 trial in HoFH, the mean age was 31 years and the oldest
334 patient in the trial was 53 years. Of the 261 patients who received KYNAMRO in the
335 pooled Phase 3 trials, 59 (22.6%) were ≥ 65 years old and 10 (3.8%) were ≥ 75 years old.
336 In the pooled Phase 3 trials, patients ≥ 65 years of age treated with KYNAMRO had a
337 higher incidence of hypertension and peripheral edema compared to placebo patients in
338 this age group, as well as compared to the younger KYNAMRO-treated age group.
339 Hepatic steatosis was also reported with greater frequency in the ≥ 65 group (13.6%)
340 compared to the <65 group (10.4%).

341

342 **8.6 Females of Reproductive Potential**

343 KYNAMRO may cause fetal harm [see *Use in Specific Populations (8.1)*]. Females who
344 become pregnant during KYNAMRO therapy should notify their healthcare provider.

345

346 Contraception

347 Females of reproductive potential should use effective contraception during KYNAMRO
348 therapy.

349

350 **8.7 Renal Impairment**

351 The safety and efficacy of KYNAMRO treatment in patients with known renal
352 impairment or in patients undergoing renal dialysis have not been established. Due to the
353 lack of clinical data and KYNAMRO's renal safety profile, KYNAMRO is not
354 recommended in patients with severe renal impairment, clinically significant proteinuria,
355 or on renal dialysis.

356

357 **8.8 Hepatic Impairment**

358 The safety and efficacy of KYNAMRO treatment in patients with known hepatic
359 impairment have not been established. KYNAMRO is contraindicated in patients with
360 clinically significant hepatic dysfunction, which may include persistent elevations of
361 transaminases. [See *Contraindications (4) and Warnings and Precautions (5.1)*]

362

363 **10 OVERDOSAGE**

364 There have been no reports of overdose with KYNAMRO treatment. In clinical trials,
365 patients receiving higher doses of KYNAMRO (300 mg and 400 mg once weekly for 13
366 weeks) experienced adverse reactions similar to the adverse reactions experienced by
367 patients receiving treatment with 200 mg once weekly but at slightly higher rates and
368 greater severity. Liver-related tests should be monitored. Although there is no information
369 on the effect of hemodialysis in treating an overdose with mipomersen, hemodialysis is

370 unlikely to be useful in overdose management since mipomersen is highly bound to
371 plasma proteins.

372

373 11 DESCRIPTION

374 KYNAMRO (mipomersen sodium) Injection is a sterile, preservative-free, clear,
375 colorless to slightly yellow, aqueous solution for subcutaneous injection. KYNAMRO is
376 supplied in single-use, 2 mL, clear glass vials or single-use, 1 mL, clear glass pre-filled
377 syringes filled to deliver 1 mL of solution containing 200 mg of mipomersen sodium (200
378 mg per 1 mL). KYNAMRO is formulated in water for injection and may include
379 hydrochloric acid and/or sodium hydroxide for pH adjustment to 7.5 – 8.5.


380 Mipomersen sodium is an oligonucleotide inhibitor of apo B-100 synthesis. ApoB is the
381 principal apolipoprotein of LDL and its metabolic precursor, very low density lipoprotein
382 (VLDL). Mipomersen inhibits synthesis of apoB by sequence-specific binding to its
383 messenger ribonucleic acid (mRNA) resulting in degradation of the mRNA through
384 enzyme-mediated pathways or disruption of mRNA function through binding alone.

385 Mipomersen sodium is a synthetic phosphorothioate oligonucleotide sodium salt, 20
386 nucleotides in length, with the following sequence:

387
$$5'-\underline{G}^{\text{Me}}\underline{C}^{\text{Me}}\underline{C}^{\text{Me}}\underline{U}^{\text{Me}}\underline{C}^{\text{Me}}\text{AGT}^{\text{Me}}\text{CTG}^{\text{Me}}\text{CTT}^{\text{Me}}\underline{C}^{\text{Me}}\underline{G}^{\text{Me}}\underline{CA}^{\text{Me}}\underline{C}^{\text{Me}}\underline{C}^{\text{Me}}-3'$$

388 where the underlined residues are 2'-O-(2-methoxyethyl) nucleosides; all other residues
389 are 2'-deoxynucleosides. Substitution at the 5-position of the cytosine (C) and uracil (U)
390 bases with a methyl group is indicated by ^{Me}.

391 Mipomersen sodium is represented by the following structural formula:



392

393 The molecular formula of mipomersen sodium is C₂₃₀H₃₀₅N₆₇O₁₂₂P₁₉S₁₉Na₁₉ and the
 394 molecular weight is 7594.9 g/mol.

395

396 12 CLINICAL PHARMACOLOGY

397 12.1 Mechanism of Action

398 Mipomersen is an antisense oligonucleotide targeted to human messenger ribonucleic
 399 acid (mRNA) for apo B-100, the principal apolipoprotein of LDL and its metabolic
 400 precursor, VLDL. Mipomersen is complementary to the coding region of the mRNA for
 401 apo B-100, and binds by Watson and Crick base pairing. The hybridization of
 402 mipomersen to the cognate mRNA results in RNase H-mediated degradation of the
 403 cognate mRNA thus inhibiting translation of the apo B-100 protein.

404 The *in vitro* pharmacologic activity of mipomersen was characterized in human hepatoma
 405 cell lines (HepG2, Hep3B) and in human and cynomolgus monkey primary hepatocytes.
 406 In these experiments, mipomersen selectively reduced apo B mRNA, protein and secreted
 407 protein in a concentration- and time-dependent manner. The effects of mipomersen were
 408 shown to be highly sequence-specific. The binding site for mipomersen lies within the

409 coding region of the apo B mRNA at the position 3249-3268 relative to the published
410 sequence GenBank accession number NM_000384.1.

411

412 **12.2 Pharmacodynamics**

413

414 Cardiac ECG Effects

415 At a concentration of 3.8 times the C_{max} of the maximum recommended dose (200 mg
416 subcutaneous injection), mipomersen does not prolong the QTc interval to any clinically
417 relevant extent.

418

419 **12.3 Pharmacokinetics**

420 Single- and multiple-dose pharmacokinetics of mipomersen in healthy volunteers and in
421 patients with FH and non-FH has shown that mipomersen plasma exposure increases with
422 increasing dose in the range of 30 mg to 400 mg.

423

424 **Absorption**

425 Following subcutaneous injection, peak concentrations of mipomersen are typically
426 reached in 3 to 4 hours. The estimated plasma bioavailability of mipomersen following
427 subcutaneous administration over a dose range of 50 mg to 400 mg, relative to
428 intravenous administration, ranged from 54% to 78%.

429

430 **Distribution**

431 Mipomersen is highly bound to human plasma proteins ($\geq 90\%$) at clinically relevant
432 concentrations (1-8 $\mu\text{g/mL}$). Mipomersen has a distribution plasma half-life of
433 approximately 2 to 5 hours.

434 With once weekly dosing, plasma trough levels increase over time and approach steady-
435 state, typically within 6 months.

436

437 **Metabolism**

438 Mipomersen is not a substrate for CYP450 metabolism, and is metabolized in tissues by
439 endonucleases to form shorter oligonucleotides that are then substrates for additional
440 metabolism by exonucleases.

441

442 **Excretion**

443 The elimination of mipomersen involves both metabolism in tissues and excretion,
444 primarily in urine. Both mipomersen and putative shorter oligonucleotide metabolites
445 were identified in human urine. Urinary recovery was limited in humans with less than
446 4% within the 24 hours post dose. Following subcutaneous administration, elimination
447 half-life for mipomersen is approximately 1 to 2 months.


448

449 **Drug Interactions**

450 No clinically relevant pharmacokinetic interactions were reported between mipomersen
 451 and warfarin, or between mipomersen and simvastatin or ezetimibe. The results of these
 452 studies are summarized in Figures 1 and 2.

453 **Figure 1: Impact of Other Drugs on Mipomersen Pharmacokinetics**


454



455
 456

457

Figure 2: Impact of Mipomersen on the Pharmacokinetics of Other Drugs



458

459

460 **Specific Populations**

461 **Renal Impairment**

462 Pharmacokinetics of KYNAMRO in patients with renal impairment has not been
 463 established [see *Use in Specific Populations (8.7)*].

464

465 **Hepatic Impairment**

466 Pharmacokinetics of KYNAMRO in patients with hepatic impairment has not been
 467 established [see *Use in Specific Populations (8.8)*].

468

469 **13 NONCLINICAL TOXICOLOGY**

470 **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

471 In a subcutaneous carcinogenicity study in mice, mipomersen sodium was administered
472 for up to 104 weeks at doses of 5, 20, 60 mg/kg/week. There were statistically significant
473 increases in the incidences of hepatocellular adenoma and combined adenoma and
474 carcinoma in female mice at 60 mg/kg/wk (2-times the systemic clinical exposure at 200
475 mg/wk, based on a body surface area comparison) for both mipomersen sodium and the
476 mouse-specific analog. This dose also resulted in statistically significant increases in the
477 incidence of hemangiosarcomas in female mice and fibrosarcomas of the skin/subcutis in
478 male mice.

479 In a subcutaneous carcinogenicity study in rats, mipomersen sodium was administered for
480 up to 104 weeks at doses of 3, 10, 20 mg/kg/wk. The incidence of fibrosarcomas of the
481 skin/subcutis and the combination of fibroma, fibrosarcomas and malignant fibrous
482 histiocytoma of the skin/subcutis was statistically significantly increased in female rats at
483 10 mg/kg/wk, at less than clinical exposure at the 200 mg/wk dose based on body surface
484 area comparisons. Both sexes of rats also had statistically significant increases in the
485 incidence of malignant fibrous histiocytoma of the skin/subcutis at 20 mg/kg/wk (at
486 clinical exposure at the 200 mg/wk dose based on body surface area comparisons).

487 Mipomersen did not exhibit genotoxic potential in a battery of studies, including the *in*
488 *vitro* Bacterial Reverse Mutation (Ames) assay, an *in vitro* cytogenetics assay using a mouse
489 lymphoma cell line, and an *in vivo* micronucleus assay in mice.

490 Mipomersen sodium had no effect on fertility in mice at doses up to 87.5 mg/kg/wk (2-
491 times clinical exposure at the 200 mg/wk dose based on body surface area comparisons).

492

493 **13.2 Animal Pharmacology and/or Toxicology**

494 The principal target organs for mipomersen pathology are the kidneys and liver. These
495 organs represent the highest distribution of compound, and exhibit microscopic changes
496 reflective of cellular uptake in macrophages. The most widespread toxicological effect of
497 mipomersen was a spectrum of inflammatory changes in numerous organs, including
498 lymphohistiocytic cell infiltrates and increases in lymphoid organ weights, associated
499 with increases in plasma cytokines, chemokines and total serum IgG. In a chronic
500 monkey study, multi-focal intimal hyperplasia with mixed inflammatory infiltrates was
501 evident in vascular beds in 2 of 6 monkeys treated for 12 months with 30 mg/kg/week
502 with a no-observed-adverse-effect-level (NOAEL) of 10 mg/kg/week (approximately
503 equal to clinical exposures anticipated from a 200 mg/wk dose based on body surface
504 area comparisons across species).

505

506 **14 CLINICAL STUDIES**

507 The safety and effectiveness of KYNAMRO, given as 200 mg weekly subcutaneous
508 injections, as an adjunct to lipid-lowering medications in individuals with HoFH were
509 evaluated in a multinational, randomized (34 KYNAMRO; 17 placebo), placebo-
510 controlled, 26-week trial in 51 patients with HoFH. A diagnosis of functional HoFH was
511 defined by the presence of at least one of the following clinical or laboratory criteria: (1)

512 history of genetic testing confirming 2 mutated alleles at the LDLr gene locus, or (2)
 513 documented history of untreated LDL-C > 500 mg/dL and at least one of the criteria (a)
 514 tendinous and/or cutaneous xanthoma prior to age 10 years or (b) documentation of
 515 elevated LDL-C > 190 mg/dL prior to lipid-lowering therapy consistent with HeFH in
 516 both parents. In case a parent was not available, a history of coronary artery disease in a
 517 first degree male relative of the parent younger than 55 years or first degree female
 518 relative of the parent younger than 60 years was acceptable.

519 The baseline demographic characteristics were well-matched between the KYNAMRO
 520 and placebo patients. The mean age was 32 years (range, 12 to 53 years), the mean body
 521 mass index (BMI) was 26 kg/m², 43% were men, and the majority (75%) were Caucasian.
 522 In 50 of 51 (98%) patients, the background therapy of maximally tolerated lipid-lowering
 523 medication included statins. In total, 44 of the 50 (88%) patients were on maximum-dose
 524 statin therapy with or without other lipid-lowering medications. Thirty-eight of the 50
 525 (76%) patients were also taking at least one other lipid-lowering medication, most
 526 commonly ezetimibe in 37 of 50 (74%) patients; patients were not on LDL apheresis.
 527 Eighty-two percent of the KYNAMRO group and 100% of the placebo group completed
 528 the efficacy endpoint at week 28. Adverse events contributed to premature
 529 discontinuation for four patients, all in the KYNAMRO group [see *Adverse Reactions*
 530 (6)].

531 The primary efficacy endpoint was percent change in LDL-C from baseline to Week 28.
 532 At Week 28, the mean and median percent changes in LDL-C from baseline were -25%
 533 (p<0.001) and -19%, respectively, for the KYNAMRO group. The mean and median
 534 treatment difference from placebo was -21% (95% confidence interval [CI]: -33, -10) and
 535 -19%, respectively. Changes in lipids and lipoproteins through the efficacy endpoint at
 536 Week 28 are presented in Table 4.

537

538 **Table 4: Response to Addition of KYNAMRO™ to Maximally Tolerated Lipid**
 539 **Lowering Medication in Patients with HoFH**

| | KYNAMRO n=34 | Placebo n=17 | |
|---|---|-------------------------------|--|
| Mean Baseline LDL-C(mg/dL) (range) | 439 (190, 704) | 400 (172, 639) | |
| Parameter (mg/dL) | Mean or Median Percent Change from Baseline to End of Treatment* | | Mean (95% CI) or Median Treatment Difference from Placebo (%) |
| LDL-C † | -25 | -3 | -21 (-33, -10) |
| Apo B † | -27 | -3 | -24 (-34, -15) |
| TC † | -21 | -2 | -19 (-29, -9) |

| | | | |
|--------------------|-----|----|----------------|
| Non-HDL-C † | -25 | -3 | -22 (-33, -11) |
| TG £ | -18 | 1 | -18 |
| HDL-C ‡£ | 15 | 4 | 11 |

540 *End of treatment represents two weeks following final dose of KYNAMRO, Last observation
 541 carried forward (LOCF).

542 †Denotes statistically significant difference between treatment groups based on the pre-
 543 specified gatekeeping method for controlling Type I error among the primary and secondary
 544 endpoints.


545 ‡The treatment effect was not consistent across the Phase 3 trials.

546 £ Medians are presented due to non-normal distribution.

547

548 LDL-C percent changes from baseline with KYNAMRO were variable among
 549 individuals with HoFH ranging from a 2% increase to an 82% reduction. The LDL-C
 550 percent changes from baseline in the placebo group range from a 43% increase to a 33%
 551 reduction. Mean LDL-C percent changes over time are presented in Figure 3.

552 **Figure 3: Mean Percent Change in LDL-C in Patients with HoFH (Completers**
 553 **Population)**



554 Placebo N:17 17 17 17 17 16 17 17
 KYNAMRO 200 mg N:28 28 28 27 28 28 27 28 28

555

556 **16 HOW SUPPLIED/STORAGE AND HANDLING**

557 KYNAMRO is supplied in single-use, 2 mL, clear glass vials or single-use, 1 mL, clear
558 pre-filled syringes with staked needles. Each single-use vial or single-use pre-filled
559 syringe of KYNAMRO is filled to deliver 1 mL of 200 mg/mL solution containing 200
560 mg of mipomersen sodium.

561 KYNAMRO is available in cartons containing 1 or 4 vials and 1 or 4 pre-filled syringes.

562 Pack of 1 vial: NDC 58468-0190-1

563 Pack of 4 vials: NDC 58468-0190-2

564 Pack of 1 pre-filled syringe: NDC 58468-0191-1

565 Pack of 4 pre-filled syringe: NDC 58468-0191-2

566 Store refrigerated KYNAMRO at 2-8 °C (36-46 °F). KYNAMRO should be protected
567 from light and kept in the original carton until time of use. When refrigeration is not
568 available KYNAMRO may be stored at or below 30 °C (86 °F), away from heat sources,
569 for up to 14 days. Do not use KYNAMRO after the expiration date on the label. This
570 product contains no preservatives; any unused drug remaining in vial after extracting 1
571 mL for injection must be safely discarded.

572

573 **17 PATIENT COUNSELING INFORMATION**

574 See FDA-approved labeling (Medication Guide)

575 Advise patients of the following:

576 Risk of hepatotoxicity [see *Warnings and Precautions* (5.1)]

577 • KYNAMRO can cause elevations in transaminases and hepatic steatosis. Discuss
578 with the patient the importance of monitoring liver-related laboratory tests before
579 taking KYNAMRO and periodically thereafter.

580

581 • Patients should be advised of the potential for increased risk of liver injury if
582 alcohol is consumed while taking KYNAMRO. It is recommended that patients
583 taking KYNAMRO should consume no more than one alcoholic drink per day.

584

585 • Advise patients to promptly report symptoms of possible liver injury, such as
586 nausea, vomiting, fever, anorexia, fatigue, jaundice, dark urine, pruritus, or
587 abdominal pain.

588

589 KYNAMRO REMS [see *Warnings and Precautions* (5.2)]

590

591 • KYNAMRO is only available through a restricted program called KYNAMRO
592 REMS and therefore, KYNAMRO is only available from certified pharmacies that

593 are enrolled in the program. Additional information may be obtained at 1-877-
594 KYNAMRO (1-877-596-2676).

595 Injection Site Reactions [see *Warnings and Precautions (5.3)*]

- 596 • Injection site reactions have been reported frequently in patients receiving
597 KYNAMRO.
- 598 • These local reactions typically consist of one or more of the following: erythema,
599 pain, tenderness, pruritus and local swelling.

600 Flu-like symptoms [see *Warnings and Precautions (5.4)*]

- 601 • Flu-like symptoms have been reported in patients receiving KYNAMRO.
- 602 • Flu-like symptoms typically occur within 2 days after an injection and include one or
603 more of the following: influenza-like illness, pyrexia, chills, myalgia, arthralgia,
604 malaise or fatigue.

605 Dosing [see *Dosage and Administration (2)*]

- 606 • The patient or caregiver should be instructed to review the KYNAMRO Medication
607 Guide and Instructions for Use carefully.
- 608 • KYNAMRO is administered as a subcutaneous injection given once a week.
- 609 • Do not remove the needle cover from the pre-filled syringe while allowing the
610 syringe to reach room temperature.
- 611 • The patient or caregiver should be instructed by a physician or an appropriately
612 qualified healthcare professional in the proper technique for administering
613 subcutaneous injections, including the use of aseptic technique.
- 614 • The patient and caregiver should be cautioned that needles or syringes must not be re-
615 used and instructed in safe disposal procedures. A puncture-resistant container for
616 disposal of used needles and syringes should be supplied to the patient along with
617 instructions for safe disposal of the full container.
- 618 • KYNAMRO should be injected into the abdomen, thigh region, or outer area of the
619 upper arm. Patients and caregivers should be advised to alternate sites for
620 subcutaneous injections. KYNAMRO should not be injected in areas of active skin
621 disease or injury such as sunburns, skin rashes, inflammation, skin infections, active
622 areas of psoriasis, or areas of tattooed skin and scarring.
- 623 • Patients and caregivers should be advised to alternate sites for subcutaneous injection.
624 The injection should be performed slowly and steadily and the needle should not be
625 withdrawn until the injection is complete.
- 626 • Protect from light. Do not mix or co-administer KYNAMRO with other products.

627 **KYNAMRO vials manufactured by:**

628 Hospira Inc.

629 McPherson, KS 67460

630

631 **KYNAMRO pre-filled syringes manufactured by:**

632 Genzyme Biosurgery

633 Ridgefield, NJ 07657

634

635 **KYNAMRO is manufactured for:**

636 Genzyme Corporation

637 500 Kendall Street

638 Cambridge, MA 02142

639 1-800-745-4447 (phone)

640

641 KYNAMRO is a trademark of Genzyme Corporation.

MEDICATION GUIDE
KYNAMRO™ (kye-NAM-roe)
(mipomersen sodium)
injection

Read this Medication Guide before you start using KYNAMRO and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.

What is the most important information I should know about KYNAMRO?

- KYNAMRO is available only through certified pharmacies that are enrolled in the KYNAMRO REMS Program. Your doctor must be enrolled in the program in order for you to be prescribed KYNAMRO.

KYNAMRO may cause serious side effects, including liver problems such as increased liver enzymes or increased fat in the liver.

- Your doctor should do blood tests to check your liver before you start KYNAMRO.
- Tell your doctor if you have had liver problems, including liver problems while taking other medicines.
- Tell your doctor right away if you have any of these symptoms of liver problems while taking KYNAMRO:
 - nausea
 - vomiting
 - fever
 - loss of appetite
 - you are more tired than usual
 - yellowing of your eyes or skin
 - dark urine
 - itching
 - stomach pain
- Drinking alcohol may increase your chance of having liver problems or make your liver problems worse. You should not have more than 1 alcoholic drink each day while using KYNAMRO.

What is KYNAMRO?

KYNAMRO is a prescription medicine used along with diet and other lipid-lowering treatments in people with homozygous familial hypercholesterolemia (HoFH) to reduce:

- LDL (“bad”) cholesterol
- total cholesterol
- a protein that carries “bad” cholesterol in the blood (apolipoprotein B)
- non-high-density lipoprotein cholesterol (non-HDL-C)

It is not known if KYNAMRO can decrease problems from high cholesterol, such as heart attack, stroke, death or other health problems.

It is not known if KYNAMRO is safe in people with high cholesterol but who do not have HoFH.

It is not known if KYNAMRO is safe and effective as an additional treatment to LDL-apheresis.

It is not known if KYNAMRO is safe and effective in people with kidney and liver problems, including people who are on kidney dialysis.

It is not known if KYNAMRO is safe and effective when used in children under the age of 18.

Who should not take KYNAMRO?

Do not take KYNAMRO if you:

- have moderate or severe liver problems or active liver disease, including people who have unexplained abnormal liver tests.
- are allergic to mipomersen or any of the ingredients in KYNAMRO. See the end of this leaflet for a complete list of ingredients in KYNAMRO.

What should I tell my doctor before taking KYNAMRO?

Before you take KYNAMRO, tell your doctor if you:

- have liver problems
- have kidney problems
- drink alcohol
- are pregnant or plan to become pregnant. KYNAMRO may cause harm to your unborn baby. If you are a female who can get pregnant, you should use effective birth control while using KYNAMRO. Talk with your doctor to find the

best method of birth control for you. If you become pregnant while taking KYNAMRO, stop taking KYNAMRO and call your doctor right away.

- are breastfeeding or plan to breastfeed. It is not known if KYNAMRO passes into your breast milk. You and your doctor should decide if you will use KYNAMRO or breastfeed. You should not do both.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Before starting a new medicine while taking KYNAMRO, even if you will only be taking it for a short time, ask your doctor or pharmacist if it is safe to take while you are using KYNAMRO.

Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How should I take KYNAMRO?

- See the **Instructions for Use** that comes with this Medication Guide for complete information on how to use KYNAMRO.
- KYNAMRO is given by injection under your skin (subcutaneous) 1 time each week. KYNAMRO is available in single-use (1 time) vials, or as a single-use pre-filled syringe.
- Take KYNAMRO exactly as your doctor tells you to take it.
- Make sure that you or your caregiver are trained by your doctor or other healthcare professional in how to inject KYNAMRO the right way.
- Do not try to give yourself or have another person give you injections at home until you or both of you understand and are comfortable with how to prepare for your dose and give the injection.
- Take KYNAMRO on the same day of the week at the same time of day.
- If you miss a dose or forget to take your dose of KYNAMRO at your usual weekly time, you can take it when you remember, unless it is less than 3 days until your next weekly dose. If it is less than 3 days until your next weekly dose, wait and take your next weekly dose at your regularly scheduled time. Do not take a double dose at the same time to make up for a forgotten or missed dose.
- It is important that KYNAMRO is at room temperature when it is injected.
- Do not mix KYNAMRO with other injectable medicines.
- Do not use KYNAMRO at the same time as other injectable medicines.
- If you use too much KYNAMRO, call your doctor right away.

- **Do not** stop taking KYNAMRO without talking to your doctor.

What are the possible side effects of KYNAMRO?

KYNAMRO can cause serious side effects, including:

- See **“What is the most important information I should know about KYNAMRO?”**
- injection site problems
- flu-like symptoms

Call your doctor right away if you have any of the serious side effects of KYNAMRO.

The most common side effects of KYNAMRO include:

- injection site problems. Skin reactions can happen in some people including redness or discoloration of the skin, pain, tenderness, itching, and swelling around the injection site. You may also get a reaction at a former site of injection, when injecting at a different site, or after an injury to an injection site.
- flu-like symptoms, including fever, chills, aches, and tiredness. These symptoms usually happen within 2 days of an injection.
- nausea
- headache

Tell your doctor about any side effect that bothers you or that does not go away.

These are not all the possible side effects of KYNAMRO. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store KYNAMRO?

- Store KYNAMRO in a refrigerator between 36°F to 46°F (2°C to 8°C). If a refrigerator is not available, KYNAMRO can be stored at or below 86°F (30°C) for up to 14 days if it is kept away from heat.
- Protect KYNAMRO from light and store in the original carton.
- Safely throw away medicine that is out of date or no longer needed.

Keep KYNAMRO and all medicines out of the reach of children.

General information about KYNAMRO

Do not use KYNAMRO for a condition for which it was not prescribed. Do not give KYNAMRO to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about KYNAMRO. You can ask your pharmacist or doctor for information about KYNAMRO that is written for healthcare professionals.

For more information, go to www.KYNARMO.com or call 1-877-KYNAMRO (1-877-596-2676).

What are the ingredients in KYNAMRO?

Active ingredient: mipomersen sodium

Inactive ingredient: sterile water, hydrochloric acid, and sodium hydroxide

This Medication Guide has been approved by the U.S. Food and Drug Administration.

KYNAMRO is manufactured for:

Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142

This Medication Guide has been approved by the U.S. Food and Drug Administration.

KYNAMRO is a trademark of Genzyme Corporation.

Issued: Month Year

Instructions for Use
KYNAMRO™ (kye-NAM-roe)
(mipomersen sodium) injection
Solution for Subcutaneous Injection
Single-use Vial

Read the Instructions for Use that come with your KYNAMRO before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment. Before you use KYNAMRO for the first time, make sure your doctor shows you the right way to use it.

This Instructions for Use is only to be used for KYNAMRO single-use vials for injection.


Do not use the KYNAMRO vial if:

- the expiration date on the container has passed.
- the packaging or seals are torn or broken, or the vial looks cracked or damaged when you receive your KYNAMRO.
- the medicine in the vial is discolored (it should be colorless to slightly yellow), or if it is cloudy or has any visible particles in it (it should be completely clear).

Supplies needed for your KYNAMRO injection:

- KYNAMRO vial
 - **NOTE:** It is important that KYNAMRO be at room temperature prior to the injection. Allow KYNAMRO to come to room temperature for at least 30 minutes. When KYNAMRO is cold, it may cause redness or sensitivity after your injection. KYNAMRO should not be heated and should be kept in original packaging to protect from light.
- 2 new needles (**Note:** the needle with the higher gauge number is smaller):
 - 22-gauge needle
 - 30-gauge needle
- 1 mL sterile syringe
- 2 alcohol wipes
- cotton ball
- puncture-proof container to dispose of the needles, syringe, and vial. See the detailed instructions for **“Dispose of used syringes, needles, and vials”** at the end of this Instructions for Use.

The figure below shows the KYNAMRO vial, the sterile syringe, and the needles that you will need.




PREPARE:

Step 1. Place supplies and wash hands. Place the supplies you will need on a clean, flat surface in a well-lit area. Wash and dry your hands well.

Step 2. Remove vial cap. With your thumb, push up and remove the plastic protective cap (see Figure A). Clean the rubber stopper with a fresh alcohol wipe (see Figure B). Allow the alcohol to dry for 15 seconds to 30 seconds.




Step 3. Attach 22-gauge or larger needle. Put a sterile 22-gauge or larger needle, with the cap still on, onto a new syringe.




Step 4. Prepare syringe for insertion into vial.

- a. Pull the cap straight off the needle to avoid bending the needle (see Figure C). **NOTE:** Hold the barrel of the syringe in one hand like a pencil or a dart. **Do not** touch the needle.




- b. Pull the plunger back, filling the syringe with air to the 0.5 mL unit marking (see Figure D).




Step 5. Insert syringe needle into vial. Push the needle through the rubber stopper and push the plunger to put air into the air space

above the liquid.




Step 6. Fill syringe. Turn the vial upside down. Position the syringe so the needle is in the liquid. Pull back on the plunger to fill the syringe to the 1 mL mark.

NOTE: Make sure the needle remains in the liquid while drawing the medicine into the syringe.



Step 7. Check the syringe.


- Remove the syringe from the vial.
- Check for air bubbles in the syringe by gently tapping on the syringe with your fingertips to make any air bubbles rise to the top (see Figure E).
- With your other hand gently push the plunger to remove the air bubbles without accidentally pushing out the medicine.
- Check to be sure that the right amount of medicine is in the syringe. If needed, repeat the steps above until 1 mL of the medicine is in the syringe without air bubbles (see Figure F).



Step 8. Remove and dispose of needle. Remove the needle from the syringe and carefully throw away the needle in a puncture-proof container.

Step 9. Attach 30-gauge needle. Put a 30-gauge needle onto the syringe (see Figure G) and remove the cap by pulling it straight off the syringe to avoid bending the needle (see Figure H).

NOTE: Hold the barrel of the syringe in one hand like a pencil or a dart. **Do not** touch the needle itself.



Step 10. Choose an injection site. KYNAMRO is injected under the skin and into the fat layer between the skin and muscles (subcutaneous tissue). KYNAMRO should be injected in the abdomen (belly), thigh, or back of the upper arm. If you choose your abdomen, do not use the area 2 inches around your belly button (navel).

NOTE: Choose a different site each time you give yourself an injection to reduce the chance of redness or pain. Avoid injecting KYNAMRO into areas of skin that are damaged, such as scars, tattoos, active skin disease, sunburns, rashes, inflammation, skin infections, or active areas

of psoriasis.




INJECT:

Step 11. Clean the injection site. Use an alcohol wipe and allow the site to dry.



Step 12. Insert the needle. Gently pinch and lift the skin around the injection site. Stick the needle straight down into your skin with a quick, firm motion. Be careful not to stick the needle into the fingers of your other hand.



Step 13. Slowly, over a period of at least 10 seconds, push down the plunger with your thumb until the syringe is empty. Once the

syringe is empty, pull the needle straight out, release the skin, and hold a clean cotton ball at the injection site. **Do not** rub the area because rubbing may cause reddening or pain at your injection site.



DISPOSE:

Step 14. Dispose of used syringes, needles and vials.

- Put your used needles, syringes, and vials in a FDA-cleared sharps disposal container right away after use.
- **Do not** throw away (dispose of) loose needles, syringes, or vials in your household trash.
- If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
 - made of a heavy-duty plastic
 - can be closed with a tight-fitting, puncture-proof lid, without sharps being able to come out
 - upright and stable during use
 - leak resistant
 - properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at:
<http://www.fda.gov/safesharpsdisposal>
- **Do not** dispose of your used sharps disposal container in your household trash unless your community guidelines permit this.
- **Do not** recycle your used sharps disposal container.

How should I store KYNAMRO?

- Store KYNAMRO in a refrigerator between 36°F to 46°F (2°C to 8°C). If a refrigerator is not available, KYNAMRO can be stored at or below 86°F (30°C) for up to 14 days if it is kept away from heat.
- Protect KYNAMRO from light and store in the original carton.
- Safely throw away medicine that is out of date or no longer needed.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

KYNAMRO is manufactured for:

Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
1-800-745-4447 (phone)

KYNAMRO is a trademark of Genzyme Corporation

Issued: January 2013

INSTRUCTIONS FOR USE
KYNAMRO™ (kye-NAM-roe)
(mipomersen sodium) injection
Solution for Subcutaneous Injection
Single-use Pre-filled Syringe

Read the Instructions for Use that come with your KYNAMRO before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment. Before you use KYNAMRO for the first time, make sure your doctor shows you the right way to use it.

This Instructions for Use is only to be used for KYNAMRO in pre-filled syringes.


Do not use the KYNAMRO pre-filled syringe if:

- the expiration date on the barrel of the container has passed.
- the packaging or seals are torn or broken, or the syringe looks cracked or damaged when you receive your KYNAMRO.
- the medicine in the pre-filled syringe is discolored (it should be colorless to slightly yellow), or if it is cloudy or has any visible particles in it (it should be completely clear).

Supplies needed for your KYNAMRO injection:

- KYNAMRO pre-filled syringe
 - **NOTE:** It is important that KYNAMRO be at room temperature prior to the injection. Allow KYNAMRO to come to room temperature for at least 30 minutes. When KYNAMRO is cold, it may cause redness or sensitivity after your injection. KYNAMRO should not be heated and should be kept in original packaging to protect from light.
- alcohol wipe
- cotton ball
- puncture-proof container to dispose of the used syringes. See the detailed instructions for the “**Dispose of used syringes**” at the end of this Instructions for Use.

The figure below shows what the pre-filled syringe for KYNAMRO looks like before and after use.



PREPARE:

Step 1. Place Supplies and Wash Hands. Place the supplies you will need on a clean, flat surface in a well-lit area. Wash and dry your hands well.


Step 2. Choose an injection site. KYNAMRO is injected under the skin and into the fat layer between the skin and the muscles (subcutaneous). KYNAMRO should be injected in the abdomen (belly), thigh, or back of the upper arm. If you choose your abdomen, do not use the area 2 inches around your belly button (navel). **NOTE:** Choose a different site each time you give yourself an injection to reduce the chance of redness or pain. Avoid injecting KYNAMRO into areas of skin that are damaged, such as scars, tattoos, active skin disease, sunburns, rashes, inflammation, skin infections, or active areas of psoriasis.



Step 3. Clean the injection site. Use an alcohol wipe and allow the site to dry.




Step 4. Remove the syringe from the tray. Peel back the foil lid from the tray. Grab the syringe from the center and pull straight out of the tray.
NOTE: Do not remove the syringe by pulling on the plunger or the cap as you may bend the needle or move the plunger.



INJECT:


Step 5. Remove the cap. Pull the cap straight off the syringe to avoid bending the needle. **NOTE:** Hold the barrel of the syringe in 1 hand like a pencil or a dart. **Do not** touch the needle.



Step 6. Insert the needle. Gently pinch and lift the skin around the injection site. Stick the needle straight down into your skin with a quick, firm motion. Be careful not to stick the needle into the fingers of your other hand.



Step 7. Slowly, over a period of at least 10 seconds, push down the plunger with your thumb until the syringe is empty. Once the syringe is empty, pull the needle straight out, release the skin, and hold a clean cotton ball at the injection site. **Do not** rub the area because rubbing may cause reddening or pain at your injection site.



Step 8. Activate safety shield. Point the needle down away from yourself and others, and then fully push down on the plunger to activate the safety shield. **Do not** try to re-cap the needle with the cap.



DISPOSE:

Step 9. Dispose of used syringes.

- Put your used syringes in a FDA-cleared sharps disposal container right away after use.
- **Do not** throw away (dispose of) loose syringes in your household trash.
- If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:

- made of a heavy-duty plastic
- can be closed with a tight-fitting, puncture-proof lid, without sharps being able to come out
- upright and stable during use
- leak resistant
- properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at:
<http://www.fda.gov/safesharpsdisposal>
- **Do not** dispose of your used sharps disposal container in your household trash unless your community guidelines permit this.
- **Do not** recycle your used sharps disposal container.

How should I store KYNAMRO?

- Store KYNAMRO in a refrigerator between 36°F to 46°F (2°C to 8°C). If a refrigerator is not available, KYNAMRO can be stored at or below 86°F (30°C) for up to 14 days if it is kept away from heat.
- Protect KYNAMRO from light and store in the original carton.
- Safely throw away medicine that is out of date or no longer needed.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

KYNAMRO is manufactured for:


Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
1-800-745-4447 (phone)

KYNAMRO is a trademark of Genzyme Corporation
Issued: January 2013

Vial Label Kynamro USA
Item No. 51045101
Rev. 11Jan2013

DRAFT


(b) (4)



Kynamro 1 Vial Carton USA
Item No. 61045101
Rev. 11Jan2013



(b) (4)

DRAFT



Kynamro 4 Vial Carton USA
Item No. 91045201
Rev. 11Jan2013

DRAFT



Label Kynamro 4 PFS USA
Item No. 51045301
Rev. 10Jan2013

DRAFT



Lid Kynamro
Item No. 41045301
Rev. 14Jan2013

DRAFT



(b) (4)

KYNAMRO™
(mipomersen sodium) injection
200 mg/mL

Pre-filled syringe contains 200 mg
of mipomersen sodium in 1 mL of solution

1 Single-use syringe

Discard unused portion

For subcutaneous injection only

Store in a refrigerator 36°F - 46°F (2°C - 8°C).
Kynamro may be stored at or below 86°F (30°C),
away from heat source, for up to 14 days.
See package insert for dosage and administration.

Manufactured by: Genzyme Biosurgery
For: Genzyme Corporation,
500 Kendall Street, Cambridge, MA 02142

NDC 58468-0191-1

Rx only

41045301

Lot:

Exp:

PEEL HERE

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHRISTINE P NGUYEN
01/29/2013